1. Background {#sec1-jcm-09-02290}
=============

Lynch syndrome is one of the most common hereditary cancer syndromes, affecting an estimated 1 in 300 individuals, based on the prevalence of underlying genetic abnormalities in the general population. It is caused by pathogenic variants affecting one of the DNA mismatch repair (MMR) genes (path_MMR): *path_MLH1*, *path_MSH2*, *path_MSH6* and *path_PMS2*, each of which results in different risks for cancer, particularly colorectal, endometrial and ovarian cancer \[[@B1-jcm-09-02290]\].

Women with Lynch syndrome (excepting *path_PMS2*) have a lifetime risk of up to 50% of developing colorectal and endometrial cancer and a lower risk (up to 17%) of developing ovarian cancer \[[@B2-jcm-09-02290]\]. Risk estimates for age-related gynecological cancer in Lynch syndrome vary by gene, as described by the Prospective Lynch Syndrome Database (PLSD). PLSD reported a cumulative incidence of endometrial and ovarian cancer at 75 years of 37% and 11% for *path_MLH1* carriers, 49% and 17% for *path_MHS2* carriers and 41% and 11% for *path_MSH6* carriers, respectively \[[@B2-jcm-09-02290]\]. Notably, female *path_MSH6* carriers are at highest risk of endometrial cancer compared with cancer in other organs \[[@B2-jcm-09-02290],[@B3-jcm-09-02290],[@B4-jcm-09-02290]\].

Whilst colonoscopy surveillance has been associated with improved survival by early detection of colorectal lesions compared with no surveillance \[[@B5-jcm-09-02290]\], there is limited evidence that gynecological cancer surveillance offers a survival benefit due to a lack of high-quality trial data \[[@B6-jcm-09-02290]\]. Nevertheless, a 98% 10-year survival from endometrial cancer has been reported by the PLSD in women who are known path_MMR carriers, suggesting that surveillance and/or increased awareness of the red flag symptoms of gynecological cancers may enable detection at early stages when cure is more likely \[[@B4-jcm-09-02290]\].

In contrast, risk-reducing hysterectomy and BSO have been shown to prevent gynecological cancer in women with Lynch syndrome \[[@B7-jcm-09-02290]\]. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome suggested that risk-reducing total hysterectomy and BSO should be offered no earlier than 35--40 years of age, following completion of childbearing, to *path_MLH1*, *path_MSH2* and *path_MSH6* carriers. However, the group concluded that there was insufficient evidence to offer risk-reducing surgery to *path_PMS2* carriers, whose risk of gynecological cancers is appreciably lower \[[@B6-jcm-09-02290],[@B8-jcm-09-02290]\]. The prescription of estrogen-only replacement therapy (HRT) until at least natural menopause (\~51 years) was strongly recommended for women who undergo risk-reducing surgery \[[@B6-jcm-09-02290]\].

In this report, we describe the current practice for hysterectomy and BSO reported by each PLSD contributing center. We also explore reasons for divergence in the participating centers at the time of the survey.

2. Methods {#sec2-jcm-09-02290}
==========

All contributing centers were asked to complete a structured survey of current practice of risk-reducing gynecological surgery by April 2019 ([Table 1](#jcm-09-02290-t001){ref-type="table"}). Data were collected via a structured questionnaire (with areas for qualitative data collection).

The survey covered questions regarding the current practice for *path_MLH1*, *path_MSH2*, *path_MSH6* and *path_PMS2* carriers, including risk-reducing hysterectomy and BSO and the timing of surgery. We asked each center about the involvement of the patient and healthcare professional stakeholders in initiating discussions about risk-reducing gynecological surgery, whether surgery was actively recommended and if so, for whom.

Data were exported to an excel file, and descriptive statistics were used to catalogue the findings. Local guidelines for gynecological surveillance and the modalities used are shown in Supplementary [Table 1](#jcm-09-02290-t001){ref-type="table"}.

3. Results {#sec3-jcm-09-02290}
==========

3.1. Survey Response {#sec3dot1-jcm-09-02290}
--------------------

We conducted the survey in 31 participating medical centers, from 18 countries. Of the thirty-one centers, 21 (68%) from 12 countries, including Germany (*n* = 5), Finland (*n* = 1), Australia (*n* = 1), Spain (*n* = 1), the United Kingdom (*n* = 2), Norway (*n* = 1), The Netherlands (*n* = 2), Italy (*n* = 3), Sweden (*n* = 1), Israel (*n* = 2), Switzerland (*n* = 1) and Argentina (*n* = 1), completed the survey ([Table 2](#jcm-09-02290-t002){ref-type="table"}).

3.2. Risk-Reducing Hysterectomy and BSO as Measures to Prevent Gynecological Cancer in Path_MMR Carriers {#sec3dot2-jcm-09-02290}
--------------------------------------------------------------------------------------------------------

Risk-reducing hysterectomy and BSO are offered in 20/21 (95%) centers for *path_MLH1* and *path_MSH2* carriers. For *path_MSH6* carriers, risk-reducing hysterectomy and BSO are offered in 19/21 (91%) centers. Fourteen out of 21 (67%) centers offer risk-reducing hysterectomy and BSO for *path_PMS2* carriers ([Table 2](#jcm-09-02290-t002){ref-type="table"}). The most common reported age at which risk-reducing surgery is currently offered is ≥40 years in path_MMR carriers. Prescription of estrogen-only HRT after premenopausal oophorectomy is recommended by 15/21 (71%) centers, across a variable age range (35--55 years).

3.3. Involvement of Stakeholders {#sec3dot3-jcm-09-02290}
--------------------------------

### 3.3.1. Risk-Reducing Hysterectomy {#sec3dot3dot1-jcm-09-02290}

Of the 21 centers, 11 provided information about which stakeholders are involved in initiating discussions about risk-reducing hysterectomy with Lynch syndrome carriers. Ten (91%) centers stated that healthcare professionals (mainly gynecologists, genetic counselors and medical geneticists) offer advice about risk-reducing hysterectomy to women with Lynch syndrome, and 6/9 (67%) centers that provided further information stated that risk-reducing hysterectomy is actively recommended. Of the 21 centers, only 4 provided information about patient engagement in discussions about risk-reducing hysterectomy. Of these four centers, one (25%) reported that risk-reducing hysterectomy is only provided upon request by Lynch syndrome carriers.

### 3.3.2. BSO {#sec3dot3dot2-jcm-09-02290}

With regards to risk-reducing BSO, 10/21 centers provided information about stakeholder involvement in these discussions. Nine (90%) centers stated that healthcare professionals (mainly gynecologists, genetic counselors and medical geneticists) offer advice to Lynch syndrome carriers about risk-reducing BSO. In 9/10 centers, risk-reducing BSO is advocated by healthcare professionals, and in 5/9 (56%), it is actively recommended. Of the 21 centers, 6 provided information about the involvement of patients in discussions about risk-reducing BSO. Three of those centers (50%) stated that surgery is only provided upon request by Lynch syndrome carriers.

4. Discussion {#sec4-jcm-09-02290}
=============

Here, we provide insight into the current management of gynecological cancer risk in women with Lynch syndrome across participating PLSD centers. We received data from 21/31 (68%) PLSD centers, incorporating practices from 12 countries worldwide. There was global agreement (\>90%) for offering both hysterectomy and BSO to *path_MLH1*, *path_MSH2* and *path_MSH6* carriers after the age of 40 years. The reported age at which risk-reducing surgery is offered is later than the minimum age (35 years) for *path_MLH1* and *path_MSH2* carriers suggested by the recent expert consensus statement \[[@B6-jcm-09-02290]\], which was based on the reported rapidly rising risk of gynecological cancers for *path_MSH2* and *path_MSH6* carriers from that age onwards \[[@B2-jcm-09-02290]\]. Despite the very low risk for gynecological cancer in *path_PMS2* carriers, risk-reducing hysterectomy and BSO are still offered by 67% of the responding centers. Interestingly, we identified no major differences between the countries, but there are some discrepancies between centers from the same country (e.g., the UK, The Netherlands and Israel). Of note, the survey was taken one year ago (April 2019), and some retrospective and prospective data studies on ovarian and endometrial cancer risk in Lynch syndrome were just being published \[[@B8-jcm-09-02290],[@B9-jcm-09-02290],[@B10-jcm-09-02290]\]. This may explain the discrepancies between centers, especially for *path_PMS2* carriers, whereby some centers (e.g., The Netherlands) have adapted their practice, but changes have not been incorporated into national guidelines yet, whilst other centers (e.g., Switzerland) rely on recommendations from European and US guidelines/statements.

Decisions about risk-reducing surgery reflect discussions between women and healthcare providers that incorporate a range of issues, including personalized risk calculations, advantages/disadvantages of risk-reducing surgery, gynecological health, medical co-morbidity, family planning, and women's values and preferences. The complexity of these individualized discussions cannot be captured in a simple survey of this nature. Nevertheless, we sought to understand more about the drivers for these discussions, whether healthcare professionals are active or passive in providing risk-reducing gynecological surgery, and whether this differs by center, country, surgery type (hysterectomy versus BSO) and affected gene. Most centers offer risk-reducing hysterectomy and/or BSO, but there is a huge variation between centers as to whether surgery is actively recommended or provided only upon patient request. This likely reflects inconsistency in national and international guidelines underpinned by a lack of high-quality published studies. There is a clear unmet clinical need for more research in this area to guide a consistent approach to risk-reducing gynecological surgery for Lynch syndrome carriers irrespective of where an individual woman lives and who is involved in her care \[[@B11-jcm-09-02290]\].

The prescription of HRT following premenopausal oophorectomy is recommended in 71% of the centers from 35 years for a variable duration of up to 55 years of age. The reported ages at which HRT is offered is not in line with the strong recommendation by the Manchester International Consensus Group that suggests HRT is offered until at least the age of natural menopause (\~51 years) \[[@B6-jcm-09-02290]\]. Some centers do not prescribe HRT at all; it is notable that the current National Comprehensive Cancer Network (NCCN) guidelines for risk management for women with Lynch syndrome do not mention prescription of HRT \[[@B12-jcm-09-02290]\]. However, estrogen protects against colorectal cancer \[[@B13-jcm-09-02290],[@B14-jcm-09-02290],[@B15-jcm-09-02290],[@B16-jcm-09-02290],[@B17-jcm-09-02290],[@B18-jcm-09-02290]\], which is particularly relevant for Lynch syndrome carriers, as well as protecting bone and cardiovascular health \[[@B19-jcm-09-02290],[@B20-jcm-09-02290]\]. Many of the well-publicized harms associated with HRT relate to its prolonged use in older women and specifically from the progestin component that is not required when the uterus is removed \[[@B21-jcm-09-02290],[@B22-jcm-09-02290]\].

Risk-reducing hysterectomy and/or BSO has been reported to prevent cancer and/or to improve survival in women with Lynch syndrome \[[@B7-jcm-09-02290]\]. For women who choose not to undergo risk-reducing surgery, an understanding of the 'red flag' symptoms for these cancers is important to trigger prompt referral for urgent investigation \[[@B23-jcm-09-02290]\]. A woman's personal risk should be used to provide individualized counselling regarding the need for risk-reducing surgery and the optimal timing of this.

5. Conclusions {#sec5-jcm-09-02290}
==============

This study provides a snapshot of the preventive gynecological recommendations provided to women with Lynch syndrome by 21 centers from 18 countries worldwide. There is a wide variation in how, when and to whom risk-reducing gynecological surgery is offered. The Manchester International Consensus Group developed guidance to harmonize the care offered to women with Lynch syndrome but noted the lack of high-quality research in this area. There is a clear need for further research so that women with Lynch syndrome can expect and receive consistent, evidence-based care for the management of their gynecological cancer risk.
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jcm-09-02290-t001_Table 1

###### 

Survey covering questions regarding the current practice with respect to prophylactic hysterectomy and/or bilateral salpingo-oophorectomy (BSO) in *path_MMR* carriers.

  Current Practice                                                                               *Path_MLH1* Carrier   *Path_MSH2* Carrier   *Path_MSH6* Carrier   *Path_PMS2* Carrier
  ------------------------------------------- -------------------------------------------------- --------------------- --------------------- --------------------- ---------------------
  Prophylactic hysterectomy                   Available (Y/N)                                                                                                      
  If so, at which age                                                                                                                                              
  If so, only if patient asks \*                                                                                                                                   
  If so, to be mentioned by counsellor \*                                                                                                                          
  If so, to be advocated by counsellor \*                                                                                                                          
  Prophylactic oophorectomy                   Available(Y/N)                                                                                                       
  If so, at which age                                                                                                                                              
  If so, only if patient asks \*\*                                                                                                                                 
  If so, to be mentioned by counsellor \*\*                                                                                                                        
  If so, to be advocated by counsellor \*\*                                                                                                                        
                                              If premenopausal oophorectomy, HRT to which age?                                                                     

\*/\*\* mutually exclusive, answer only one for each gene; \*/\*\* please specify who the counsellor would be (more than one if applicable), e.g. gynecologist, medical geneticist, genetic counsellor, GP, other.

jcm-09-02290-t002_Table 2

###### 

Currently recommended practice for females with path_MMR variants in the Prospective Lynch Syndrome Database (PLSD) by country.

  Countries         Number of Centers   *Path_MLH1 and Path_MSH2 Carriers*   *Path_MSH6 Carriers*   *Path_PMS2 Carriers*             
  ----------------- ------------------- ------------------------------------ ---------------------- ---------------------- ---- ---- ----
  Germany           5                   5                                    5                      5                      5    5    5
  Finland           1                   1                                    1                      1                      1    1    1
  Australia         1                   1                                    1                      1                      1    1    1
  Spain             1                   1                                    1                      1                      1    1    1
  UK                2                   2                                    2                      2                      2    1    1
  Norway            1                   1                                    1                      1                      1    1    1
  The Netherlands   2                   2                                    2                      2                      2    0    0
  Italy             3                   3                                    3                      3                      3    1    1
  Sweden            1                   1                                    1                      1                      1    1    1
  Israel            2                   2                                    2                      1                      1    1    1
  Switzerland \*    1                   0                                    0                      0                      0    0    0
  Argentina         1                   1                                    1                      1                      1    1    1
  *Total*           21                  20                                   20                     19                     19   14   14

\*: There is no national guidelines or statements for female Lynch syndrome patients yet; BSO: bilateral salpingo-oophorectomy.

[^1]: These authors contributed equally.
